Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns

We read with great interest the study by Lei and colleagues about the impact of antiviral therapy (AVT) on survival outcomes of patients with hepatitis B virus (HBV)-associated intrahepatic cholangiocarcinoma (ICC), which concluded that the patients who received AVT (5-yr overall survival [OS], 43.0%; 5-yr relapse-free survival [RFS], 29.5%) could achieve better long-term outcomes compared to the others who revealed low (5-yr OS, 33.5%; RFS, 28.3%) and high (5-yr OS, 20.5%; RFS, 13.5%) viral levels, respectively.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research